Company news
Aptamer Group Plc (LSE:APTA) news
Every Aptamer Group Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Appointment of Joint Corporate Broker
August 20, 2026
Director Fee Shares and Grant of Options
August 14, 2026
Form 8.3 - [APTITUDE SOFTWARE GROUP PLC - 21 07 2026] - (CGAML)
July 22, 2026
Form 8.3 - [APTITUDE SOFTWARE GROUP PLC - 14 07 2026] - (CGAML)
July 15, 2026
Aptamer initiates Ebola diagnostic test programme
July 8, 2026
Programme and technical development update
June 25, 2026
Rapid testing programme for fortified foods
June 8, 2026
Result of Retail Offer and Posting of Notice of GM
March 31, 2026
Retail Offer to raise up to £0.5 million
March 26, 2026
Interim Results and Notice of Investor Webinar
March 25, 2026
Launch of targeted radiopharmaceutical programme
March 18, 2026
Technical Feasibility for Pathogen Detector
February 17, 2026
Optimer® Technology in Launched Library Prep Kit
February 11, 2026
Contract wins and first cash licensing receipts
January 29, 2026
Trading update - Media comment and speculation
January 7, 2026
Half Year Trading Update
January 7, 2026
Aptamer signs licensing agreement with Alphazyme
December 23, 2025
Licensing agreement with Twist Bioscience
December 16, 2025
Results of 2025 Annual General Meeting
November 27, 2025
AGM Statement
November 27, 2025
Strong contract wins build commercial momentum
November 14, 2025
New contract with top five pharma company
November 4, 2025
Posting of Annual Report and Notice of AGM
November 3, 2025
Full Year Results for the 12mths to 30 June 2025
October 14, 2025
New contract with top 10 pharma
October 13, 2025
Notice of Results, Analyst & Investor Presentation
October 10, 2025
Major top 3 global pharma contract win
October 8, 2025
Investor Event and Presentation
September 26, 2025
New contract with Metir plc
September 11, 2025
Notification of dealings by a director/PDMR
September 9, 2025
Therapeutic development agreement with Invizius
September 2, 2025
Block Listing Interim Review
August 28, 2025
Biomarker Discovery Service Launch
August 27, 2025
Update on licensing and development progress
August 22, 2025
Exercise of warrants
August 19, 2025
Holding(s) in Company
August 18, 2025
Contract extension with global pharma partner
August 18, 2025
Investor Technical Webinar
August 8, 2025
Investor Webinar
July 31, 2025
Trading Update
July 31, 2025
Result of General Meeting
July 24, 2025
Additional work commissioned by Unilever
July 21, 2025
Issue of Equity in lieu of Non-Exec Director Fees
July 18, 2025
Posting of Circular and Notice of General Meeting
July 8, 2025
Placing to raise £2.0 million
July 4, 2025
Liver fibrosis breakthrough with Optimer® platform
June 30, 2025
Agreement with global life sciences leader
June 25, 2025
Unilever second Optimer development programme
May 30, 2025
Aptamer Announces New Data at ASGCT
May 15, 2025
Optimer licensing agreements and repeat contracts
May 15, 2025